Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
05/2005
05/12/2005US20050101661 Cyclooxygenase inhibitors; musculoskeletal and cardiovascular disorders; antiinflammatory agents
05/12/2005US20050101657 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative
05/12/2005US20050101641 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
05/12/2005US20050101635 Delivering to an external portion of the body passageway of a patient in need of a therapeutically effective amount of an antihistamine or decongestant to treat inflammatory diseases
05/12/2005US20050101632 Treating inflammation of the skin or mucous membrane by topical administration of an anti-inflammatory amount of dimethicone in the absence of any other anti-inflammatory agent
05/12/2005US20050101615 Pyridopyrimidine or naphthyridine derivative
05/12/2005US20050101612 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
05/12/2005US20050101609 Quinazoline derivatives as kinase inhibitors
05/12/2005US20050101606 Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient
05/12/2005US20050101591 Fused bicyclic pyridine derivative as tachykinin receptor antagonist
05/12/2005US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders
05/12/2005US20050101529 Protein modification and maintenance molecules
05/12/2005US20050101004 Screening for a compound to inhibit the urge for urinary incontinence by detecting activation of KCNQ protein in the host cell; measuring the membrane potential of the host cell and selecting the compound whose presence causes hyperpolarization in themembrane potential of the host cell
05/12/2005US20050100902 5-cyano-1h-indole derivatives as antagonist of the inerleukine-8 receptors
05/12/2005US20050100617 Method for improving age-related physiological deficits and increasing longevity
05/12/2005US20050100589 Transdermal administration of ace inhibitors
05/12/2005CA2544310A1 New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
05/12/2005CA2543745A1 Methods of organ regeneration
05/11/2005EP1529062A2 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction
05/11/2005EP1529031A1 Acylated arylcycloalkylamines and their use as pharmaceuticals
05/11/2005EP1528923A1 N-((3-oxo-2,3-dihydro-1h-isoindol-1-yl)acetyl)guanidine derivatives as nhe1-inhibitors for the treatment of infarction and angina pectoris
05/11/2005EP1417172A4 Process for the preparation of amorphous form of torsemide
05/11/2005EP1397363B1 5-ethyl-imidazotriazinones
05/11/2005EP1363899B1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
05/11/2005EP1254138B1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
05/11/2005EP1076563B1 Dipeptide caspase inhibitors and the use thereof
05/11/2005CN1615439A Genes encoding g-protein coupled receptors and methods of use therefor
05/11/2005CN1615307A Process and intermediates for pyridazinone antidiabetic agents
05/11/2005CN1615300A Benzimidazole derivatives and their use as GNRH antagonists
05/11/2005CN1615299A Xanthine oxidase inhibitors
05/11/2005CN1615155A Anti-proliferative composition
05/11/2005CN1615149A Drug mobilizing pluripotent stem cells from tissue into peripheral blood
05/11/2005CN1615134A Pharmaceutical compositions comprising valsartan and NEP inhibitors
05/11/2005CN1615123A Bilayer pharmaceutical tablets comprising telmisartan and diuretic and their preparation
05/11/2005CN1615122A Pharmaceutical formulation comprising bicalutamide
05/11/2005CN1200939C Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/11/2005CN1200735C Model animal of mesangial cell proliferative nephritis
05/11/2005CN1200714C Use of diterpenoid triepoxides as anti-proliferative agent
05/11/2005CN1200700C Pharmaceutical tramadol salts
05/11/2005CN1200614C Health diet for canine
05/10/2005US6890959 Such as cis-(4-dimethylaminomethyl-3-hydroxy-3-(3-methoxy-phenyl)-cyclohexanone for treatment of pain, inflammation, allergies, depression, drug/alcohol abuse, gastritis, itching, cardiovascular/repiratory diseases, epilepsy, and diarrhea
05/10/2005US6890952 Administering cyclic substituted aminomethyl compounds for the preparation of a drug for the treatment of pain, urinary incotinence, itching, tinnitus aurium or diarrhea in a mammal
05/10/2005US6890937 Inhibiting the activity of one or more of MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibitory activity against MMP-1
05/10/2005US6890928 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
05/10/2005US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
05/10/2005US6890925 Treating insulin resistance, hypertension, angina, ischemia, renal disease or Raynaud's disease, by administering pyrazole derivatives such as 1-(p-(morpholinocarbonylamino)phenyl)-3,5-di(trifluoromethyl)pyrazole
05/10/2005US6890922 For treatment of erectile dysfunction as well as female sexual dysfunction, incontinence, and hypertrophy of the prostate; inhibitors of cGMP-metabolizing phosphodiesterases (cGMP= cyclic guanosine monophosphate)
05/10/2005CA2250569C Novel phenanthridines substituted in the 6 position
05/10/2005CA2116192C Highly concentrated tcf pharmaceutical preparations
05/06/2005WO2005040121A2 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
05/06/2005WO2005040108A1 Prolinamide derivatives as sodium and/or calcium channel blockers or selective mao-b inhibitors
05/06/2005WO2005039602A1 Pharmacologically functional water and use thereof
05/06/2005WO2004064736A3 Treatment of benign prostatic hyperplasia using energolytic agents
05/06/2005WO2004002939A3 Aminoalcohol derivatives
05/06/2005WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
05/06/2005WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis
05/06/2005CA2543552A1 Use of neurokinin antagonists in the treatment of urinary incontinence
05/06/2005CA2543404A1 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor
05/06/2005CA2542682A1 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
05/06/2005CA2541894A1 Amino alcohol derivative, medicinal composition containing the same, and use of these
05/06/2005CA2540817A1 Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
05/06/2005CA2540782A1 Diazabicyclononene derivatives and their use as renin inhibitors
05/06/2005CA2539967A1 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
05/05/2005US20050096479 Novel succinate salt of O-desmethyl-venlafaxine
05/05/2005US20050096469 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists
05/05/2005US20050096468 Inhibitors of histone deacetylase
05/05/2005US20050096394 Racemic tamsulosin free base in solid state; preparation by precipitating the free base with a base from an acid addition salt in a water and/or a lower alcohol solvent
05/05/2005US20050096388 Compositions and methods for treating or preventing diseases of body passageways
05/05/2005US20050096321 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates
05/05/2005US20050096320 potent inhibitors of cyclic guanosine 3',5'-monophosphate-metabolizing phosphodiesterases (cGMP-PDEs)/phosphodiesterase isoenzymes PDE-I, PDE-II, PDE-V; therapeutic, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilatory, natriuretic and diuretic effects; erectile dysfunction
05/05/2005US20050096316 Quinoline derivatives(2)
05/05/2005US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic
05/04/2005EP1528066A1 Aryl 5-thio-d-glucopyranoside derivatives and remedies for diabetes containing the same
05/04/2005EP1528058A1 Polymorphic crystalline forms of celecoxib
05/04/2005EP1527171A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
05/04/2005EP1527074A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
05/04/2005EP1527051A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
05/04/2005EP1527046A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments
05/04/2005EP1526895A2 Methods for treating carbonic anhydrase mediated disorders
05/04/2005EP1526869A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
05/04/2005EP1526855A2 Pharmaceutical compositions for the treatment of urinary incontinence
05/04/2005EP1526852A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
05/04/2005EP1411881B1 5ht2c receptor modulators
05/04/2005EP1395582B1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
05/04/2005EP1377164A4 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
05/04/2005EP1259477B1 Aminoadamantane derivatives as therapeutic agents
05/04/2005EP1246790B1 Substituted 1 and 2 naphthol mannich bases
05/04/2005EP1124810B1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
05/04/2005EP1119567B1 Quinazoline derivatives
05/04/2005EP0781340B1 Vaccine against group A Streptococcal infection
05/04/2005CN1612864A Novel alkansulfonamides as endothelin antagonists
05/04/2005CN1612852A Lipoxin A4 analogs
05/04/2005CN1612745A Methods for slowing senescence and treating and preventing diseases associated with senescence
05/04/2005CN1612739A Method for treating or preventing inflammatory diseases
05/04/2005CN1612729A 2-aryl-propionic acid and medicine composition containing same
05/04/2005CN1611259A Cordyceps militaris tablet and its preparing method
05/04/2005CN1611246A Medicine for treating uraemia
05/04/2005CN1200000C Cyclie somatostatin analogs
05/04/2005CN1199987C Basic monocyclic compounds having NK2 antagonist action, processes for their preparation and formulations containing them
05/04/2005CN1199954C Benzodiazepine derivatives
1 ... 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 ... 562